The Cardiomyopathy and Lens Cataract Mutation in αB-crystallin Alters Its Protein Structure, Chaperone Activity, and Interaction with Intermediate Filaments in Vitro*

(Received for publication, April 29, 1999, and in revised form, July 27, 1999)

Ming Der Perngs§, Paul J. Muchowski§, Paul van den IJssel‡, Gabrielle J. S. Wu¶, Aileen M. Hutcheson†, John I. Clark†, and Roy A. Quinlan***

From the ‡Department of Biochemistry, Medical Science Institute, The University, Dundee DD1 5EH, United Kingdom and the Departments of §Biological Structure and ¶Ophthalmology, University of Washington, Seattle, Washington 98195-7420

Desmin-related myopathy and cataract are both caused by the R120G mutation in αB-crystallin. Desmin-related myopathy is one of several diseases characterized by the coaggregation of intermediate filaments with αB-crystallin, and it identifies intermediate filaments as important physiological substrates for αB-crystallin. Using recombinant human αB-crystallin, the effects of the disease-causing mutation R120G upon the structure and the chaperone activities of αB-crystallin are reported. The secondary, tertiary, and quaternary structural features of αB-crystallin are all altered by the mutation as deduced by near- and far-UV circular dichroism spectroscopy, size exclusion chromatography, and chymotryptic digestion assays. The R120G αB-crystallin is also less stable than wild type αB-crystallin to heat-induced denaturation. These structural changes coincide with a significant reduction in the in vitro chaperone activity of the mutant αB-crystallin protein, as assessed by temperature-induced protein aggregation assays. The mutation also significantly altered the interaction of αB-crystallin with intermediate filaments. It abolished the ability of αB-crystallin to prevent those filament-filament interactions required to induce gel formation while increasing αB-crystallin binding to assembled intermediate filaments. These activities are closely correlated to the observed disease pathologies characterized by filament aggregation accompanied by αB-crystallin binding. These studies provide important insight into the mechanism of αB-crystallin-induced aggregation of intermediate filaments that causes disease.

Desmin-related myopathy (DRM)† can be caused by mutations either in the intermediate filament protein desmin, or in the small heat shock protein αB-crystallin. Although several mutations in the intermediate filament protein desmin have been linked with DRM (1, 2), so far only a single mutation, R120G, in the small heat shock protein αB-crystallin has been identified (3). A characteristic disease pathology links the different causes of DRM, which consists of aggregates of intermediate filaments containing αB-crystallin present in the muscle cells of affected individuals (3, 4).

Other diseases, such as Alexander’s disease (5) and drug-induced hepatitis (6), are also characterized by intermediate filament aggregates. These aggregates are typically co-associated with αB-crystallin (7) despite the fact that they involve different intermediate filament proteins. This suggests that the association of αB-crystallin with intermediate filament aggregates is independent of the specific intermediate filament protein but is rather a generic response to this pathological rearrangement of intermediate filaments. These data establish a clear link between αB-crystallin, intermediate filaments, and the disease-induced aggregation of intermediate filaments (8). The mechanism of intermediate filament aggregation and the role of small heat shock proteins in this process has yet to be addressed.

The recent assessment of sHSP activity in vitro has been based upon chaperone assays using either heat (9–11) or chemically unfolded substrates (12). These have been extremely useful for studying the role of ATP (13), post-translational modifications (11, 14–17), and specific αB-crystallin residues (18–22) in the chaperone activity of sHSPs. These studies mimic the role of sHSPs in stressed cells, but they do not identify the physiological targets or the role of sHSPs in un-stressed cells.

The sHSPs are expressed in unstressed cells (8, 23–25) and sometimes at very high levels (26, 27). In unstressed, non-diseased cells of muscle (23), astrocyte (24, 25), and epithelial and lenticular origins (27), αB-crystallin is found associated with intermediate filaments. In the eye lens, there is a unique cytoskeletal filament that is a stable complex of α-crystallin, comprising both αB- and αA-crystallin, and lens intermediate filaments (28). This is called the beaded filament. Similar structures can be generated in vitro under appropriate co-aggregation conditions (29). These studies show that the association of sHSPs with intermediate filament networks is not just a stress-induced event (30), but is a feature of normal cells, and suggest a general role for sHSPs in intermediate filament biology.

Small HSPs bind to assembly competent intermediate filament proteins. This was demonstrated in the lens where a soluble complex of α-crystallin and intermediate filament proteins was immunopurified from lens cytosol (27, 31). It was subsequently demonstrated that sHSPs could inhibit GFAP as
as well as vimentin assembly in vitro (27). These data indicated that the association of sHSPs with intermediate filament proteins is not restricted to the filamentous form, but includes soluble intermediate filament complexes. From these observations, it is clear that sHSPs have the potential to influence intermediate filament assembly (29).

Recently, another aspect of the interaction of sHSPs with intermediate filaments was identified (32). Using a simple viscosity-based assay, sHSPs were shown to prevent gel formation by intermediate filaments, presumably by blocking non-covalent filament-filament interactions (32). These studies suggested a physiologically important link between intermediate filaments and sHSPs. In a cellular context, this link may prevent inappropriate interactions between bundled intermediate filaments (32). Abrogation of this sHSP function could lead to intermediate filament aggregate formation. This is not only relevant to DRM but also to other human diseases where this phenotype is a pathological hallmark such as Alexander’s disease.

In this study, the structural and functional properties of the R120G aB-crystallin are compared with those of the wild type protein. Using several different in vitro assays, the effect of the mutation upon the chaperone activity of aB-crystallin has been studied. The UVCD, size exclusion chromatography and proteolytic studies all suggest that the mutation has affected the secondary, tertiary, and quaternary structure of aB-crystallin. The mutation also causes a significant reduction in the heat-induced denaturation and a reduction in the in vitro chaperone activity of the protein. In order to understand how the aB-crystallin mutation could cause intermediate filament aggregation as seen in DRM, its effect upon the association with intermediate filaments was studied. The data show that R120G aB-crystallin was incapable of preventing filament-filament interactions that lead to the formation of an intermediate filament gel in vitro. This was accompanied by an apparent increase in the binding of R120G aB-crystallin to intermediate filaments. These data suggest that DRM resulting from the R120G mutation in aB-crystallin occurs as a progressive accumulation of intermediate filament aggregates brought about by the altered interaction of aB-crystallin with intermediate filaments.

**MATERIALS AND METHODS**

**Expression Constructs for Recombinant aB-crystallins—**Total RNA was isolated from a sample of human soleus muscle (RNasey kit, Qiagen) and converted into cDNA (Life Technologies, Inc.; SuperScript kit). Human aB-crystallin cDNA was amplified from this cDNA using oligonucleotides 5'-AGCACCAGGATCCATCGCC-3' and 5'-CTATTTTCTTTGGGGCTCTG-3' as forward and reverse primer, respectively. The amplified product was cloned into the PGEM-T Easy vector (Promega) and the sequence confirmed against the GenBank data base entry (accession no. S45630). The R202G mutation was introduced by two-step polymerase chain reaction using the PGEM-T Easy (Promega) and then subcloned. After verification of the sequences both the wild type and R120G aB-crystallin cDNAs were subcloned into the NdeI and EcoRI sites of the vector pET23b (Novagen).

**Expression of Recombinant aB-Crystallins—**Recombinant human aB-crystallins were expressed in BL21(plysDE3) in the expression vector pET23b. Recombinant protein expression was induced using 0.5 mM isopropyl-1-thio-β-D-galactopyranoside for 4 h after the cultures had reached an OD600 of 0.6. Harvested bacterial pellets were resuspended in TEN buffer (50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 300 mM NaCl, 0.2 mM PMSF, and 0.1% v/v of protease inhibitor mixture (Sigma)) and lysed by several freeze/thaw cycles. A supernatant fraction containing the soluble proteins including the recombinant sHSPs was prepared by centrifuging the lysate at 15,000 rpm in a JA20 rotor at 4 °C for 30 min. The supernatant was then dialyzed against column buffer.

**Preparation of GFAP, Native, and Recombinant aB-crystallins—**GFAP was purified from porcine spinal cord by axonal flotation as described previously (33). GFAP was then fractionated into either neuronal intermediate filament proteins using DE52 (Whatman) in 8 M urea, 10 mM Tris-HCl, pH 8.0, 5 mM EDTA, and 25 mM 2-mercaptoethanol. The proteins were eluted with a 0–200 mM NaCl linear gradient. All column procedures were carried out at room temperature. Recombinant aB-crystallin was purified by both non-denaturing (32) and denaturing methods. In the latter, two diethylaminoethyl (DEAE) column steps were used. The supernatant fraction obtained from the bacteria was loaded onto the first column comprising TSK-DEAR 650M (Merck Ltd.) in 20 mM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM MgCl2, 1 mM EDTA, 1 mM DTT, 0.2 mM PMSF and eluted with a 20–250 mM NaCl gradient. The sHSP-enriched fractions were pooled and dialyzed into buffer containing 6 M urea, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1 mM DTT, 0.2 mM PMSF. This was then loaded onto a DE52 column equilibrated in the same buffer. Proteins were eluted with a 0–200 mM NaCl gradient. All column steps were carried out at 4 °C. Column fractions were checked for homogeneity by SDS-PAGE. Protein concentrations were determined by the Bradford protein assay.

**Analytical Size Exclusion Chromatography—**Analytical size-exclusion chromatography was performed on a Biosec-SF4000, 7-μm 300 x 7.8-mm column using a Hewlett-Packard high performance liquid chromatograph with the following mobile phase: 0.1 M potassium phosphate, pH 7.0 and 0.2 mM NaCl, at a flow rate of 0.5 mL/min. High molecular weight protein standards (Amersham Pharmacia Biotech) were used to calibrate the column. The standard deviation of the molecular masses of wild type aB-crystallin/aB-crystallin mutants was determined from the peak width at its half-height in six independent experiments.

**Proteolytic, Spectroscopic, and in Vitro Chaperone Analyses—**Proteolysis of wild type aB-crystallin/aB-crystallin mutants was performed as described previously (22, 35). CD spectra were measured as described previously (36, 37). The presented CD spectra are the average of 16 scans, smoothed by polynomial curve fitting. The fit was checked with a statistical test so that the original data was not over-smoothed. To calculate molar ellipticity, a residue molecular weight of 115 was assumed. The proteins were dissolved in 20 mM sodium phosphate (pH7.1) and used at concentrations of 0.5 and 1.0 mg/ml for far- and near-UVCD, respectively, as determined from calculated extinction coefficients based on a protein amino acid sequence as described previously (38, 39). The pathlength of the cells was 10 mm for near-UVCD and 1.0 mm for far-UVCD spectroscopy.

Temperature-dependent precipitation of wild type and R120G aB-crystallin was measured in a Beckman DU640 spectrophotometer equipped with a Peltier temperature controlled cuvette holder. The rate of temperature increase was 0.1 °C/min. Proteins were dialyzed into 20 mM sodium phosphate, pH 7.1, and the concentration adjusted to 0.5 mg/ml prior to the assay. First derivative calculation was used to determine the temperature at which 50% precipitation had occurred.

Temperature-induced aggregation assays using citrate synthase (10) and alcohol dehydrogenase (11) as target proteins were performed as described (13, 40).

**Intermediate Filament Assembly, Binding, and Viscosity Assays Involving aB-crystallin—**As the sedimentation assay as developed by Nicholl and Quinlan (27) was used to assess the ability of sHSPs to inhibit filament assembly. Purified porcine GFAP was used for these studies. aB-crystallins were added to GFAP in 8 M urea, 20 mM Tris-HCl, pH 8.0, 5 mM EDTA, 25 mM 2-mercaptoethanol prior to the assembly assay. The final dialysis was against assembly buffer: 10 mM Tris-HCl, pH 7.0, 25 mM 2-mercaptoethanol, 50 mM NaCl. The experiments were performed at room temperature. Dialyzed samples were layered onto a 0.95 μm sucrose cushion in the assembly buffer and centrifuged at 80,000 x g for 30 min at 20 °C in a Beckman TL100 rotor using a TL100 benchtop ultracentrifuge. The pellet and supernatant fractions were compared by SDS-PAGE as described previously (27).

For the intermediate filament binding assay, aB-crystallins were preincubated with GFAP in 8 M urea, 20 mM Tris-HCl, pH 8.0, 5 mM EDTA, 25 mM 2-mercaptoethanol and then stepwise dialyzed into 10 mM Tris-HCl, pH 8.0, 25 mM 2-mercaptoethanol. Assembly of the GFAP intermediate filaments and binding of the aB-crystallins was then induced by addition of a 20-fold concentrated binding buffer (BB) to give a final concentration of 100 mM imidazole-HCl, pH 6.8, 0.5 mM DTT and incubation at the indicated temperature.

The gel formation assay was based upon a method used to monitor
actin binding protein activity by falling ball viscometry (41). Filament assembly was promoted exactly as described for the binding assay by addition of the 20-fold concentrated BB. 100 µl of sample was loaded into a glass tube to be used in the viscosity assay. This was then immersed in a 37 °C water bath for 1 h prior to conducting the gel formation assay. A ball was then placed into the tube, and the ability of the solution to support the ball was monitored.

Electron Microscopy—Protein samples were diluted to 100–200 µg/ml, and negatively stained using 1% w/v uranyl acetate. Grids were examined in a Jeol 1200EX TEM, using an accelerating voltage of 80 kV.

RESULTS

Structure and Stability Characteristics of the R120G αB-Crystallin Compared with Wild Type—The effect of the disease causing mutation R120G on the structure of αB-crystallin was examined using near- and far-UV CD spectroscopy. The wild type and mutant αB-crystallin were expressed in Escherichia coli using a pET-based vector system and purified to homogeneity by ion exchange chromatography. The sample purity was assessed by SDS-PAGE and is presented in Fig. 1. Using recombinantly produced proteins, the far-UV CD spectrum (200–250 nm) was measured for both wild type and mutant αB-crystallin (Fig. 2, A and B). At 25 °C (Fig. 2A), the far-UV CD spectrum of wild type αB-crystallin contained a peak minimum at approximately 215 nm that is consistent with previous UVCD analyses showing a high percentage of β-sheet/β-turn structure in αB-crystallin (34, 37, 42). When tested under identical conditions, the R120G mutant displayed a peak minimum that was shifted to a slightly shorter wavelength and had a significant (44%) increase in negative molar ellipticity in comparison to wild type αB-crystallin at 220 nm (Fig. 2A). A second measurement was made for both proteins at 45 °C to assess protein stability at temperatures utilized in the chaperone assays (Fig. 2B). While the magnitude of the peak minimum (215 nm) for wild type αB-crystallin increased approximately 22% at 45 °C, there was no increase for the R120G mutant (Fig. 2B).

At 25 °C, the near UVCD spectrum of wild type αB-crystallin included four positive ellipticity peaks below 290 nm and a large negative peak at approximately 295 nm (Fig. 3A), consistent with past studies using αB-crystallin (34, 37, 42). In stark contrast, peaks below 290 nm in the near-UVCD of the R120G mutant were shifted significantly toward negative ellipticity values at 25 °C and only a small negative peak was observed at 295 nm (Fig. 3A). For wild type αB-crystallin, increasing the temperature from 25 to 45 °C resulted in a large shift in ellipticity from positive to negative values below 290 nm, but had essentially no effect on the ellipticity of the 295 nm peak (Fig. 3B). For the R120G mutant, an increase from 25 to 45 °C resulted in only a modest shift toward negative ellipticity values below 290 nm, and did not significantly affect the ellipticity at 295 nm (Fig. 3B). Both the far- and near-UVCD data indicate that the R120G mutation has altered the secondary and tertiary structure of the αB-crystallin.

The quaternary structure of R120G αB-crystallin was altered, as assessed by six independent size exclusion chromatography analyses. The protein complexes formed by the R120G αB-crystallin mutant were larger (Mₚ = 823,000 ± 131,000) compared with the wild type (Mₚ = 633,000 ± 80,000) and more disperse, as seen by the broader size distribution given by the standard deviations.

Since the structure of αB-crystallin was affected by the R120G mutation, we decided to assess its temperature stability. Protein aggregation was detected by light scattering (Fig. 4) and showed that both wild type and R120G αB-crystallin did not aggregate up to 55 °C. Above this temperature, the mutated protein started to aggregate with precipitation 50% complete at 57.2 °C, whereas the wild type αB-crystallin remained soluble up to 63 °C, showing 50% precipitation at 64.5 °C. Furthermore, the aggregation of the R120G αB-crystallin occurred over a wider temperature range than that of the wild type protein (Fig. 4). Thus, the mutation does appear to affect the stability of the protein, but only at higher (>55 °C), non-phys-
spectra (Fig. 2, A indicates that the stability of the mutated protein was not assessed as a function of temperature from 25 to 85 °C by light scattering at 360 nm. Protein concentration was 0.5 mg/ml in 20 mM sodium phosphate, pH 7.1. The temperature was increased by 0.1 °C/min. Temperatures at midpoint of precipitation were calculated to be 64.5 and 57.2 °C for wild type and R120G B-crystallin, respectively. Note the different slopes of precipitation for the wild type and the mutant proteins.

To assess whether the R120G mutation affected the stability of αB-crystallin below 55 °C, the temperature dependence of the ellipticity at 205 and 217 nm was studied by far-UVC (data not shown). A gradual conformational transition was shown between 25 °C and 55 °C for the wild type, but not the mutated αB-crystallin. This is consistent with the far-UVC spectra (Fig. 2, A and B, cf. spectra at 25 °C versus 45 °C) and indicates that the stability of the mutated protein was not affected below 55 °C.

The Effect of the R120G Mutation upon the Chymotryptic Digestion of αB-crystallin—Chymotrypsin has been used to assess the susceptibility of αB-crystallin to proteolysis (22, 35). ATP has been shown to increase the protection of some of these sites in the α-crystallin domain against chymotryptic digestion (22, 35). These assays were used to evaluate the effects of the R120G mutation upon the availability of the chymotryptic sites for digestion as another indicator of changes in the structural characteristics of αB-crystallin (Fig. 5). The R120G mutation did make the chymotryptic sites more accessible compared with the wild type (Fig. 5), as the R120G mutant was digested faster than wild type αB-crystallin. The pattern of proteolytic products produced was qualitatively similar but not the same. Protection of the chymotrypsin sites was afforded upon addition of ATP to both the R120G and wild type αB-crystallin (Fig. 5). Thus, at this level, the differences in the digestion characteristics of R120G αB-crystallin suggested that there had indeed been some structural changes as a result of the mutation, but these did not appear to significantly alter the region(s) of αB-crystallin involved in interacting with ATP.

In Vitro Chaperone Assays—Prior to the discovery of the physiological substrates for αB-crystallin, in vitro assays were developed based upon heat-induced aggregation of proteins to assess the chaperone activity of αB-crystallin. Two were selected to cover a range of chaperone: substrate concentrations and also a range of temperatures (10, 11). As shown in Table I, R120G αB-crystallin was worse than the wild type αB-crystallin in both chaperone assays. The R120G mutant was also tested at molar ratios of 2:1 and 10:1 (protein:αB-crystallin) in the alcohol dehydrogenase-based chaperone assay, similar results to those obtained at a 1:1 ratio (Table I). In addition, at both 10:1 and 5:1 (protein:αB-crystallin) in the alcohol dehydrogenase-based chaperone assay, similar results to the 20:1 ratio were obtained (Table I). Therefore, it is reasonable to expect that the mutation will compromise the ability of αB-crystallin to perform its chaperone role in muscle and lens cells.
These conditions (in vitro) developed that assess the interaction of GFAP (B-crystallin) with Rosenthal fibers, which contain GFAP filaments coaggregated with aB-crystallin in the neurodegenerative disease Alexander’s disease (5). It is also a type III intermediate filament protein closely related to desmin (43) with similar structural features and mechanisms of assembly.

In Figs. 6 and 7, the effect upon intermediate filament assembly (Fig. 6) and the ability to bind to intermediate filaments (Fig. 7) was examined. These assays are conducted at different pH and salt conditions to optimize for the inhibition of assembly and binding to intermediate filaments, respectively (30, 32). As can be seen in Fig. 6, R120G aB-crystallin was reduced in its ability to inhibit the assembly of the intermediate filament protein, GFAP. Compared with the assembly of GFAP in the

| Protein assay     | Wild type aB-crystallin | R120G aB-crystallin |
|-------------------|-------------------------|---------------------|
| Alcohol dehydrogenase (ADH): protein ratio = 20:1 | 29 ± 2 | 90 ± 7 |
| Citrate synthase: protein ratio = 1:1; assay temperature = 45 °C | 9 ± 1 | 37 ± 6 |

**Fig. 6. Effect of wild type and R120G aB-crystallin on GFAP assembly in vitro.** In the assembly inhibition assay, GFAP was assembled in vitro (A) in the presence of wild type aB-crystallin (B) and R120G aB-crystallin (C) in a molar ratio of 1:2 at 22 °C. The supernatant (S) and pellet fractions (P) were analyzed by SDS-PAGE and stained with Coomassie Blue R250. The positions of GFAP and aB-crystallin are indicated (B and C). Under these conditions of assembly, the pellet fraction (B) contained 50% of the GFAP, whereas in the supernatant (C), 90% of GFAP remained in the supernatant. (A, lane 2). Notice that under similar experimental conditions, nearly all the wild type aB-crystallin remained in the supernatant fractions in the absence (B, lane 1) and presence of GFAP (B, lane 3). In the presence of R120G aB-crystallin (C), >80% of the GFAP is found in the pellet (P; C, lane 4). In the presence of R120G aB-crystallin, the soluble GFAP remaining in the supernatant (C, lane 3) is reduced compared with the assembly of GFAP with wild type aB-crystallin (B, lane 3) but greater than the control assembly for GFAP (A, lane 1). Notice that only the R120G aB-crystallin bound to the filament in the pellet fraction (C, lane 4) in complete contrast to wild type aB-crystallin (B, lane 4) under similar experimental conditions. In the absence of GFAP filaments, most R120G aB-crystallin remained soluble (C, lane 1) with only a very small proportion sedimenting under these conditions (C, lane 2).

**Fig. 7. Binding of wild type and R120G aB-crystallin to GFAP filaments in vitro.** In this assay, the GFAP assembly was conducted under conditions that promoted aB-crystallin binding to intermediate filaments (32). The binding is a temperature-dependent process (30, 32), and the three temperatures selected are indicated above the relevant gel lanes (A–C). The gel (P) and supernatant (S) fractions were analyzed by SDS-PAGE and stained with Coomassie blue R250. GFAP assembled efficiently into filaments under these assay conditions at temperatures of 22, 37, and 44 °C (A). Most of the GFAP is present in the pellet fractions (A, lanes 2, 4, and 6, labeled P), the small proportion of GFAP remaining in the supernatant (A, lanes 1, 3, and 5, respectively, labeled S) varies with temperature. In the absence of GFAP, wild type (B, lanes 1, 3, and 5) and R120G aB-crystallin (C, lanes 1, 3, and 5) remained almost entirely soluble (labeled S). If GFAP is included in the assay, both wild type aB-crystallin (B, cf. lanes 8, 10, and 12) and R120G aB-crystallin (C, cf. lanes 8, 10, and 12) were sedimented with the GFAP filaments. This temperature-dependent, as an increasing proportion of wild type aB-crystallin and R120G aB-crystallin was found in the pellet fractions (B and C, lanes 8, 10, and 12). Note that in the presence of GFAP, an appreciable proportion of the R120G aB-crystallin was pelletable even at 22 °C (C, lane 8). At 44 °C, all the R120G aB-crystallin was present in the pellet fraction (C, lane 10). The wild type aB-crystallin was found in the pellet fractions at 37 °C (B, lane 10) and 44 °C (B, lane 12), but larger proportion remained in the soluble fractions at both temperatures (B, lanes 9 and 11, cf. lanes 11 and 12).

**TABLE I**

| Table I: The chaperone activities of aB-crystallin and R120G aB-crystallin compared using the alcohol dehydrogenase and citrate synthase assays |
|-------------------|-------------------------|---------------------|
| Alcohol dehydrogenase (ADH): protein ratio = 20:1 | 29 ± 2 | 90 ± 7 |
| Citrate synthase: protein ratio = 1:1; assay temperature = 45 °C | 9 ± 1 | 37 ± 6 |

**TABLE II**

| Table II: Summary of the data collected for the effect of aB-crystallin and the R120G mutant on gel formation by intermediate filaments as monitored by a falling ball viscometry assay |
|-------------------|-------------------------|---------------------|
| Chaperone added to assay | GFAP gel formation as indicated by the ball position in the viscometer |
| No addition | Top |
| aB-crystallin | Bottom |
| R120G aB-crystallin | Top |
FIG. 8. Visualization of intermediate filaments assembled in the presence of wild type and R120G αB-crystallin. Samples were taken at the completion of the viscosity assay and processed using the negative staining technique for electron microscopy. In the presence of wild type αB-crystallin (A), the intermediate filaments formed were long and sometimes had αB-crystallin particles attached (arrows). The filaments were generally not clumped in this preparation. In contrast, filaments co-assembled in the presence of R120G αB-crystallin (B) were clumped (large
R120G Mutation Alters αB-Crystallin Structure and Function

The absence of αB-crystallin (Fig. 6, lanes 1 and 2), the R120G αB-crystallin was still partially to inhibit GFAP assembly (Fig. 6, lanes 3 and 4). Moreover, a sizeable proportion of R120G αB-crystallin was found in the pellet fraction (Fig. 6C, lane 4), even at 22 °C, the temperature of this assay. The wild type αB-crystallin remained almost completely soluble under these conditions (Fig. 6B, lane 4). This was the first indication that R120G αB-crystallin bound more avidly to intermediate filaments than the wild type protein.

The increased binding of R120G αB-crystallin (Fig. 7C) to GFAP filaments compared with the wild type protein (Fig. 7B) was a dramatic effect of the mutation. Even at 37 °C, R120G αB-crystallin was found to bind almost completely to the pelletable GFAP filaments, whereas the wild type αB-crystallin was only partially bound (<20%). This increased binding was consistent at different molar ratios, from 1:2 to 2:1 (sHSP to GFAP, respectively) and was apparently unaffected by the presence of 1 mM ATP (data not shown).

The increased binding of R120G αB-crystallin to intermediate filaments might be expected to increase its ability to prevent filament-filament interactions either indirectly by steric hindrance or directly by obscuring the filament-filament interaction sites. Using falling ball viscometry, this hypothesis was tested. The assay was developed so that GFAP forms a protein gel in the tube in the absence of αB-crystallin. The buffer conditions are the same as those used for the filament binding assay. This gel is capable of supporting the ball used in the viscosity assay. Addition of αB-crystallin prevents gel formation and so permits the ball to sink to the bottom of the tube (32). This is the result of inhibiting non-covalent filament-filament interactions rather than preventing filament formation as these assay conditions were similar to those used in the filament binding assay (Fig. 7), where no loss of sedimentable GFAP was observed (see also Ref. 32). As expected, after assembly of GFAP in the absence of sHSP in the control tube, a gel formed preventing the ball from falling. The presence of wild type αB-crystallin in the assay mixture at a 2:1 molar ratio to GFAP prevented the filaments formed from supporting the ball in the viscometer. In contrast, the mutant R120G αB-crystallin appeared completely ineffective at inhibiting gel formation and thus the ball was unable to enter the viscometer. Similar results were obtained for the ratios 1:2 and 2:1, sHSP to GFAP, respectively, and in the presence of 1 mM ATP (data not shown). Table II summarizes data obtained from three separate experiments.

The data from the viscosity assays have demonstrated that the R120G mutation abolished the ability of αB-crystallin to prevent gel formation by failing to inhibit filament-filament interactions required in this process, despite the increased ability of the mutant R120G αB-crystallin to bind to intermediate filaments (Fig. 7).

Visualization of the αB-crystallin Intermediate Filament Complex by Electron Microscopy—To examine the association of αB-crystallin with the GFAP filaments during the binding/viscosity assays, samples were examined using negative staining techniques and electron microscopy (Fig. 8). At 37 °C, limited binding of wild type αB-crystallin to GFAP filament was observed (Fig. 8A, arrows), whereas the R120G αB-crystallin particles were very closely associated with filaments (Fig. 8B, arrows) with no particles left unbound. In the absence of GFAP filaments, both wild type (Fig. 8C) and R120G αB-crystallin (Fig. 8D) formed discrete particles approximately 15–20 nm in diameter (Fig. 8, C and D, arrows). These observations correlated with the binding assay results (Fig. 7, B and C), where almost all of the mutant αB-crystallin bound the GFAP filaments compared with a much smaller proportion of the wild type protein. From the electron micrographs, it appears that the increased binding of the mutant αB-crystallin resulted in a very extensive coating of the intermediate filaments, leading to filament bundling (Fig. 8B).

DISCUSSION

The R120G mutation in αB-crystallin affects a highly conserved residue among the whole sHSP family (44, 45). It is important for the function of αA- and αB-crystallin as mutating this residue causes the human diseases, cataract and DRM (3), respectively. Other mutational studies using the Mycobacterium tuberculosis sHSP, HSP16.3, and the mammalian sHSPs HSP27 and αA-crystallin (21) also show this highly conserved arginine residue is structurally very important as it is part of a β-strand involved in subunit interactions (21). Recently, the crystal structure of the Methanococcus jannaschii ssHSP, HSP16.5, has been described (47), and this provided the first atomic details of this conserved arginine residue. From these data, a direct or indirect role for the disease causing arginine residue in subunit-subunit interactions was proposed (48). Although a recent study reported on the structural and chaperone-like properties of R120G αB-crystallin (49), we initiated our studies to investigate the interaction with intermediate filaments, the physiologically relevant target of αB-crystallin given the fact the mutation causes intermediate filament aggregation in the disease DRM (3).

Secondary, Tertiary, and Quaternary Structure of αB-crystallin Is Altered by the Mutation R120G—The far- and near-UVCD data presented here for the recombinant αB-crystallin (Figs. 2 and 3) correlate well with previously published data (22, 34, 37, 42). Increasing the temperature from 25 to 45 °C resulted in shifts in ellipticity values in the far- (50) and near-UV (50, 51) for wild type αB-crystallin that are consistent with a conformational change. The far- and near-UVCD spectra obtained for the R120G αB-crystallin demonstrated that the mutation affected the secondary and tertiary structure of the protein. Interestingly, the UVCD spectrum of R120G αB-crystallin at 25 °C appeared similar to that obtained for the wild type αB-crystallin at 45 °C, suggesting that the R120G αB-crystallin already existed in a more open, even partially unfolded, conformation at 25 °C. In the closely related protein, αA-crystallin, mutation of the equivalent arginine residue (Arg-116) to a cysteine and subsequent spin label modification also changed the secondary, tertiary and quaternary structure of the protein (52). The R120G mutation in αB-crystallin modified the protein structure such that the accessibility of the cryptomycotic sites was increased (Fig. 5).

Changes in the quaternary structure were therefore expected and this is substantiated by the results obtained from size exclusion chromatography. The R120G mutation induced an increase in the average Mr and a broadening of the Mr range of αB-crystallin. A similar effect upon the Mr and therefore the quaternary structure of αA-crystallin was also observed (21, 52) when the equivalent arginine (Arg-116) was changed. In the case of HSP27, oligomerization of the α-crystallin domain (21) was affected by mutating the equivalent arginine (Arg-140), but here the Mr decreased. Obviously, while it can be concluded that this conserved arginine performs a key structural role, the effect of changing this residue is not necessarily the same for all the different sHSPs.

---

Co-aggregation between intermediate filaments and R120G αB-crystallin particles was seen (B, arrows). In the absence of intermediate filaments, wild type (C) and R120G αB-crystallin (D) both formed discrete 15–20 nm particles (arrowheads). Bar = 100 μm.
The R120G Mutation Affects the Stability of αB-crystallin at Elevated Temperatures—At elevated temperatures it has been shown that α-crystallin adopts a more disordered structure (53). A conformational transition with a midpoint at 60–62 °C was observed by Fourier-transform infrared spectroscopy, differential scanning calorimetry, and circular dichroism (53). Using the latter method and monitoring the temperature dependence of ellipticity at 205 and 217 nm, a gradual transition was observed for wild type, but not R120G αB-crystallin, over the temperature range of 25–55 °C (see also Fig. 2A). Thus, in contrast to α-crystallin (50, 53), consisting of αA- and αB-crystallin subunits, αB-crystallin alone does show a gradual conformational transition in this temperature range. This is not seen for R120G αB-crystallin, as expected from comparing the CD spectra at 25 and 45 °C, which are very similar (Fig. 2B). At 64.5 °C and 57.2 °C, however, the heat-induced precipitation of wild type and R120G αB-crystallin, respectively, was 50% complete as measured by light scattering. The different profile of temperature-induced protein aggregation of R120G αB-crystallin compared with wild type αB-crystallin may reflect the increased polydispersity of the mutant protein complexes, but this needs further experimentation.

These data do indicate, however, that αB-crystallin is first stabilized by αA-crystallin, as α-crystallin does not precipitate even at 100 °C (54). Second, these data indicate that the mutation has increased the susceptibility of the protein to temperature-induced unfolding leading to protein precipitation (Fig. 4). Therefore, the mutation decreases protein stability, but the effects are most readily seen at non-physiological temperatures. Nevertheless, the more important question is whether these structural and stability changes caused by the R120G mutation affect the biological activity of αB-crystallin.

Previous studies made a very important correlation between structural changes in α-crystallin proteins and their chaperone activity (12, 50, 55). Using hydrophobic probes, a transition at 30 °C was identified. The exposure of these hydrophobic surfaces was correlated with an increase in the observed chaperone activity of the α-crystallin proteins (12, 50). It has been suggested that the polydisperse quaternary structure of αB-crystallin oligomers (56) is an important feature of the chaperone activity (12). In other studies on αA-crystallin, however, it has been possible to uncouple the changes in secondary and quaternary structure from the chaperone activity (52). Thus, although the R120G mutation causes changes in the protein structure and stability, it is important to assess the effect of the mutation upon the chaperone function of αB-crystallin.

Effect of R120G Mutation upon αB-crystallin Activity—In vitro assays (9) have been developed to study the protein chaperone function of αB-crystallin utilizing the ability of αB-crystallin to protect other proteins against either heat- or chemically induced denaturation (e.g. Refs. 10 and 11). These proteins do not necessarily represent physiological targets for the chaperone function of αB-crystallin, but they have allowed this key function to be studied in vitro. The studies presented here demonstrate that the chaperone function of αB-crystallin is significantly compromised, although not completely abolished toward these non-physiological substrates (Table I). In fact, it appeared that R120G-αB-crystallin was a major part of the insoluble pellet with both alcohol dehydrogenase and citrate synthase as target proteins (data not shown), as also reported for lactalbumin (49), suggesting that binding does not absolutely correlate with chaperone activity. Although these are important assays, they do not address the most obvious feature of DRM, which is the collapse of the intermediate filament network into characteristic aggregates containing αB-crystallin (3, 4). Several in vitro assays were used to investigate the effects of αB-crystallin on intermediate filaments (27, 30, 32). The results presented here show some loss in the ability of R120G αB-crystallin to inhibit intermediate filament assembly (Fig. 6), but the most dramatic changes concerned the interaction of R120G αB-crystallin with assembled intermediate filaments. First, the mutation caused αB-crystallin to bind more avidly to intermediate filaments (Fig. 7). Second, R120G αB-crystallin could no longer prevent gel formation by intermediate filaments (Table II). The increase in binding was visualized (Fig. 8) in the negatively stained samples of the intermediate filament-αB-crystallin complexes formed at 37 °C. In the presence of wild type αB-crystallin, limited binding to the assembled intermediate filaments was observed (Fig. 8A). In stark contrast, the R120G αB-crystallin bound avidly to the assembled intermediate filaments and even appeared to induce filament clumping (Fig. 8B). Filament lengths were comparable in both samples and so, as expected from the sedimentation assay results (Fig. 8; see also Ref. 57), the differences in the solution viscosity were entirely due to the different αB-crystallins. The data show the mutation in αB-crystallin affects all the different aspects of the interaction with intermediate filaments, but the key aspect would appear to be the change in the activity of αB-crystallin with respect to assembled intermediate filaments. The mutation caused increased binding to intermediate filaments, which appears to actively encourage filament-filament interactions. We propose that this, coupled with the loss of the ability of R120G αB-crystallin to prevent those filament-filament interactions seen in the viscosity assay gels, will lead to intermediate filament aggregation. Our observations are supported by the disease pathology that is typified by intermediate filament aggregation coupled with the association of αB-crystallin (3). It is important to realize that both mutations in αB-crystallin and intermediate filament proteins cause such characteristic pathologies. Our data suggest that a similar change in the association of sHSPs as caused by intermediate filament mutations will explain these disease pathologies.

The R120G mutation in αB-crystallin obviously compromises αB-crystallin function in vivo, but the disease phenotypes were not seen at birth, appearing only in early adulthood (3) and affecting only the lenses and muscles of individuals carrying the mutation, while the other tissues that express αB-crystallin had no phenotype. Several factors could explain these observations. First, both wild type and R120G αB-crystallin will be expressed together (3). Second, the R120G mutation apparently does not completely abolish the chaperone activity (Table I). Finally, both the eye lens (58) and muscle express other sHSPs, sometimes in high concentrations (59, 60), which could change the sensitivity of the different tissues. Collectively, these factors might help delay the onset of the disease and select the eye lens and muscles as those tissues to be affected by the R120G mutation in αB-crystallin.

Note Added in Proof—Similar effects on the structure and insulin-chaperone activity of αA-crystallin were observed when the equivalent arginine (Arg116) was mutated to cysteine (61).

REFERENCES
1. Goldfarb, L. G., Park, K. Y., Cervenakova, L., Gorakhtova, S., Lee, H. S., Vasuncelos, O., Nagle, J. W., Semino-Mora, C., Sivakumar, K., and Dalakas, M. C. (1998) Nat. Genet. 19, 402–403
2. Munez-Marmol, A. M., Strasser, G., Isamat, M., Coulombe, P. A., Yang, Y., Roca, X., Vela, E., Mate, J. L., Coll, J., Fernandez-Figueroes, M. T., Navas-Palacios, J. J., Ariza, A., and Fuchs, E. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11313–11317
3. Vicart, P., Caron, A., Guicheney, P., Li, Z., Prevost, M. C., Faure, A., Chateau, D., Chapon, F., Tome, F., Dupret, J. M., Paulin, D., and Fardeau, M. (1998) Nat. Genet. 20, 92–95
4. Goebel, H. H., and Bornemann, A. (1993) Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 64, 127–135
5. Iwaki, T., Kume-Iwaki, A., Liem, R. K. H., and Goldman, J. E. (1989) Cell 57, 71–78
